Normafenac (Cefuroxime Sodium)

Cefuroxime sodium belongs to the cephalosporin class and works by binding to penicillin‑binding proteins on the bacterial cell wall. This binding blocks the final step of peptidoglycan cross‑linking, weakening the wall and causing the bacteria to burst due to osmotic pressure, ultimately leading to bacterial death.

The dosage of Normafenac is individualized by the prescribing clinician based on the type and severity of infection, patient age, weight, renal function, and route of administration (intramuscular or intravenous). Only a qualified healthcare provider can determine the appropriate regimen.

Safety data for cefuroxime sodium in pregnancy and lactation are limited. It should be used only when the potential therapeutic benefit justifies any possible risk to the fetus or infant. Healthcare providers should evaluate the risk‑benefit ratio before prescribing to pregnant or nursing mothers.

To request Normafenac, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any necessary import documentation.

Normafenac (cefuroxime sodium) is a second‑generation cephalosporin offering broader Gram‑negative coverage than first‑generation agents while retaining activity against many Gram‑positive organisms. Compared with third‑generation cephalosporins, it has a more favorable safety profile but a narrower spectrum against resistant Gram‑negative bacteria.

Normafenac should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept away from moisture and direct sunlight to maintain product stability. Do not refrigerate unless specifically instructed by the manufacturer.

Normafenac is supplied as an injectable solution for intramuscular or intravenous administration. The route, infusion rate, and injection site are determined by the prescribing clinician based on the infection type, patient condition, and local clinical guidelines.

The most serious risks include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and serum‑sickness‑like reactions. Prompt medical attention is required if symptoms like rash, difficulty breathing, persistent diarrhoea, or fever develop after treatment.

Normafenac is contraindicated in patients with a known hypersensitivity to cefuroxime, other cephalosporins, or any component of the formulation. Caution is also advised for individuals with a history of severe penicillin allergy due to possible cross‑reactivity.